Exelixis (EXEL) Stock
Key stats
- Market cap
- $17.25B
- Price / Earnings ratio
- 19.5x
- EPS (TTM)
- $3.45
- Volume
- Loading
- 52-week high
- $73.69
- 52-week low
- $39.71
- EPS vs analyst estimate
- +23.8%Q3 FY25 · $0.78 vs $0.63
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with EXEL
Recent news
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
EXEL
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
EXEL
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
EXEL
What Exelixis (EXEL) Said on Its Q3 Earnings Call
What Exelixis (EXEL) Said on Its Q3 Earnings Call
EXELNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 65.82
- MACD 12/26/9
- 2.89
- EMA 9 of MACD
- 2.81
- MACD histogram
- 0.09
- SMA 50
- $61.86
- Price above SMA 50
- EMA 50
- $63.07
- Price above EMA 50
- SMA 200
- $51.97
- Price above SMA 200
- EMA 200
- $53.37
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.54 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
EXELExelixis (EXEL) International Revenue in Focus: Trends and Expectations
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
EXELEXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
EXELWhat Exelixis (EXEL) Said on Its Q3 Earnings Call
What Exelixis (EXEL) Said on Its Q3 Earnings Call
EXEL
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
EXEL
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates
EXEL
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
EXEL
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
EXEL
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
EXEL
Exelixis Rises with Earnings on Tap
Exelixis Rises with Earnings on Tap
EXELNews tone: automated (AI) classification of the article's content, not a price prediction.
About Exelixis
Exelixis, Inc., a biotechnology company strong focus on discovering, developing, and commercializing innovative therapies for treating cancer, the company has made significant strides in advancing its pipeline of targeted oncology treatments. Exelixis is renowned for its flagship drug, Cabometyx (cabozantinib), which has gained approvals for various cancer indications, demonstrating the company's dedication to improving patients' lives. Through strategic collaborations, cutting-edge research, and a commitment to scientific excellence, Exelixis continues to be at the forefront of delivering breakthrough therapies in the fight against cancer.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael M. Morrissey Ph.D. | CEO, President & Director | 1961 |
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board | 1948 |
| Mr. Christopher J. Senner | Executive VP & CFO | 1968 |
| Dr. Brenda J. Hefti J.D., Ph.D. | Senior VP & General Counsel | 1974 |
| Dr. Dana T. Aftab Ph.D. | Executive Vice President of Research & Development | 1964 |
| Mr. Patrick Joseph Haley M.B.A. | Executive Vice President of Commercial | 1976 |
| Dr. William Berg M.D. | Senior Vice President of Medical Affairs | — |
| Dr. Stefan Krauss Ph.D. | VP & Head of Business Development | — |
| Mr. Andrew Ross Peters | Senior Vice President of Strategy | — |
| Ms. Deborah Burke CPA | Senior VP of Finance & Controller | 1956 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 65.82
- MACD 12/26/9
- 2.89
- EMA 9 of MACD
- 2.81
- MACD histogram
- 0.09
- SMA 50
- $61.86
- Price above SMA 50
- EMA 50
- $63.07
- Price above EMA 50
- SMA 200
- $51.97
- Price above SMA 200
- EMA 200
- $53.37
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $54.00
- Average
- $62.56
- High
- $78.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.1 | +11.5 | ||||||||||
| 2022 | -5.6 | +11.5 | +8.5 | -2.4 | -19.1 | +12.7 | -3.0 | -15.4 | -13.9 | +1.4 | +1.7 | -5.9 |
| 2023 | +8.1 | -2.7 | +11.1 | -6.1 | +2.4 | -1.4 | +3.0 | +14.1 | -3.9 | -7.3 | +3.8 | +9.3 |
| 2024 | -9.1 | +0.7 | +6.7 | -0.9 | -1.1 | +2.5 | +5.4 | +7.5 | +0.5 | +26.2 | +6.9 | -6.4 |
| 2025 | -2.3 | +17.7 | -4.2 | +7.6 | +10.7 | +2.8 | -17.0 | +0.4 | +11.1 | -6.1 | +16.1 | +0.9 |
| 2026 | -5.1 | +2.9 | +4.5 | +1.0 | +15.6 | +8.2 | -1.7 | -0.8 | +2.7 | +19.8 | +0.8 |
